Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06638021 · ClinicalTrials.gov registry record · NA
Targeted EHR-based Communication of Diagnostic Uncertainty in the ED
A NA study of Diagnostic Uncertainty, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06638021: Recruiting NA study of Diagnostic Uncertainty, sponsored by Thomas Jefferson University.
NCT06638021 is a NA study of Diagnostic Uncertainty that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06638021, a NA study of Diagnostic Uncertainty, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the clinical trial is to evaluate the preliminary effectiveness and the implementation feasibility of the Targeted EHR-based Communication about Uncertainty (TECU) strategy in improving the quality of care transitions from the emergency department (ED) to home. The overall specific aims related to the trial are to test the preliminary effectiveness of TECU compared to standard of care in reducing patient uncertainty and return ED visits and evaluate the adoption of TECU, exploring patient and clinician barriers and facilitators to TECU implementation.
Primary Outcome
The Uncertainty Scale (U-Scale) is a 30-item scale designed to measure patient-level uncertainty related to acute symptoms independent of underlying disease. The scale uses a 5-point Likert-style response format, asking respondents to indicate agreement with each statement from "strongly disagree" (1) to "strongly agree" (5) and leading to a nominal score range of 30-150. Higher scores indicate greater uncertainty.
Conditions Studied
Interventions
- BEHAVIORAL Targeted EHR-based Communication of Diagnostic Uncertainty (TECU)
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2027-07-01 |
| Phase | NA |
What NCT06638021 shows while recruiting
NCT06638021 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Diagnostic Uncertainty appearing as the primary indexed condition, and to 1 intervention - of which Targeted EHR-based Communication of Diagnostic Uncertainty (TECU) is the first listed.
NCT06638021 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06638021 about?
NCT06638021 is a clinical study titled "Targeted EHR-based Communication of Diagnostic Uncertainty in the ED". The goal of the clinical trial is to evaluate the preliminary effectiveness and the implementation feasibility of the Targeted EHR-based Communication about Uncertainty (TECU) strategy in improving the quality of care transitions from the emergency department (ED) to home. The overall specific aims ...
What is the current status of trial NCT06638021?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-11-05. Estimated completion is 2027-07-01.
What conditions does trial NCT06638021 study?
This clinical trial studies the following conditions: Diagnostic Uncertainty.
What interventions are being tested in trial NCT06638021?
The interventions under investigation include: Targeted EHR-based Communication of Diagnostic Uncertainty (TECU) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06638021?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06638021 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06638021's enrollment target sits among peer trials
300 330th of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI